[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 858,724
  • Shares Outstanding, K 73,270
  • Annual Sales, $ 0 K
  • Annual Income, $ -38,180 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta -0.51
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.26

Options Overview Details

View History
  • Implied Volatility 146.77% (-3.25%)
  • Historical Volatility 55.05%
  • IV Percentile 33%
  • IV Rank 7.56%
  • IV High 970.42% on 02/17/26
  • IV Low 79.43% on 02/24/26
  • Expected Move (DTE 5) 0.43 (3.63%)
  • Put/Call Vol Ratio 0.94
  • Today's Volume 905
  • Volume Avg (30-Day) 701
  • Put/Call OI Ratio 0.44
  • Today's Open Interest 11,528
  • Open Int (30-Day) 9,854
  • Expected Range 11.30 to 12.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 3
  • High Estimate $-0.26
  • Low Estimate $-0.35
  • Prior Year $-0.21
  • Growth Rate Est. (year over year) -47.62%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.16 +27.93%
on 07/29/26
11.94 -1.88%
on 08/14/26
+1.85 (+18.74%)
since 07/14/26
3-Month
7.47 +56.89%
on 05/19/26
11.94 -1.88%
on 08/14/26
+2.81 (+31.54%)
since 05/14/26
52-Week
4.35 +169.43%
on 11/25/25
11.94 -1.88%
on 08/14/26
+5.68 (+94.04%)
since 08/14/25

Most Recent Stories

More News
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Planning to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Pivotal phase 3 clinical data...

CADL : 11.72 (-0.68%)
Can Candel Therapeutics Repeat Its Earnings Beat Without Burning More Cash?

Barchart Research What to Expect from CADL Earnings CADL Generated August 12, 2026 Current Price $10.68 EPS Estimate $$-0.22 Consensus Rating Strong Buy Average Move 5.26% Can Candel Therapeutics Repeat...

CADL : 11.72 (-0.68%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 11.72 (-0.68%)
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026

NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 11.72 (-0.68%)
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston

NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 11.72 (-0.68%)
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 08, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 11.72 (-0.68%)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEEDHAM, Mass., July 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies...

CADL : 11.72 (-0.68%)
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors

Phase 3 clinical trial will evaluate aglatimagene besadenovec plus valacyclovir in combination with continued pembrolizumab versus standard-of-care docetaxel chemotherapy in patients with metastatic, non-squamous,...

CADL : 11.72 (-0.68%)
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer

Appointment supports planned Biologics License Application (BLA) submission in the fourth quarter of 2026 and potential 2027 launch of aglatimagene besadenovec in localized prostate cancer NEEDHAM,...

CADL : 11.72 (-0.68%)
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Peer reviewed publication details pivotal data, demonstrating 30% improvement in disease-free survival (DFS) in patients with localized prostate cancer undergoing standard-of-care radiotherapy with curative...

CADL : 11.72 (-0.68%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 13.00
2nd Resistance Point 12.47
1st Resistance Point 12.10
Last Price 11.72
1st Support Level 11.19
2nd Support Level 10.66
3rd Support Level 10.29

See More

52-Week High 11.94
Last Price 11.72
Fibonacci 61.8% 9.04
Fibonacci 50% 8.15
Fibonacci 38.2% 7.25
52-Week Low 4.35

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.